David Wheeler talks about the findings of the FIGARO trial, the use of finerenone in people with type 2 diabetes, and how this may fit with SGLT2 inhibitors.

Finerenone reduces the risk for new-onset heart failure, as well as hospitalization for heart failure (HHF) and death from HF, in people with type 2 diabetes and albuminuric chronic kidney disease, the latest analysis of FIGARO-DKD study data show.

Nephrologist Ian de Boer joins primary care physician Amrit Lamba to discuss how the recent approval of finerenone and extension of the dapagliflozin label is likely to influence the treatment of kidney disease in people with type 2 diabetes.

A prespecified analysis of the FIDELIO-DKD trial shows that finerenone reduces the risk for cardiovascular disease events in people with type 2 diabetes and chronic kidney disease, irrespective of whether they have pre-existing heart disease.

Rossing highlighted the recommendation for glucagon-like peptide-1 receptor agonists in people with type 2 diabetes, because of their strong cardioprotective effects, and the option of a nonsteroidal mineralocorticoid receptor antagonist (ie, finerenone), also for people with type 2 diabetes if they have residual renal risk.

They suggest that “[t]he effect of canagliflozin on hyperkalaemia may make combined treatment with [SGLT2 inhibitors, RAAS blockade and finerenone] more feasible.”